Trial
NCT02697136
CER-001 Therapy as a Novel Approach to Treat Genetic Orphan Diseases
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Cerenis Therapeutics, SA
Collaborators
—
Condition
Familial Hypoalphalipoproteinemia
Intervention
CER-001
Why stopped
Lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-07-22